Zh Nevrol Psikhiatr
-
Zh Nevrol Psikhiatr · Jan 2015
Randomized Controlled Trial[Ways to optimize the treatment of patients with discogenic-venous lumbosacral radiculomyeloischemia].
Treatment of patients with neurological manifestations of degenerative-dystrophic lesions of the spine must be integrated and optimized from the perspective of pathogenesis. Antiedematous therapy is an important moment that takes into account the development of localized swelling affected the spinal structures. We studied the efficacy of L-lysine aescinat in the treatment of patients with discogenic-venous lumbosacral radiculomyelopathy. ⋯ The comparison of neurological status dynamics during treatment of inpatients has shown that neurological symptoms reduce more effectively in patients treated with L - lysine aescinat (by 75% during the first 3-5 days) and in a greater number of the patients (77.5% vs 55% in the control group). The authors' experience has shown that venous micro- and macro-circulation disorders play an important role in the pathogenesis of lower lumbar disk hernia. Clinical manifestations of these disorders are segmental and conductive spinal motor disorders in myotomes and sensitivity. Quantitative determination of vibration sensitivity (tuning fork test) is pathognomonic for radiculomyeloischemia. Vein tonics and antiedemics, including L - lysine aescinat as one of the most effective drugs, exert a pathogenetic effect on spondylic and discogenic nervous system disturbances.
-
Zh Nevrol Psikhiatr · Jan 2013
Randomized Controlled Trial Comparative Study[Dynamics of cognitive and emotional-volitional disorders in children and adolescents with refractory epilepsy during the treatment with levetiracetam].
We examined 76 children and adolescents (45 boys (59.2%), 31 girls (40.8%), aged from 6 to 17 years (mean age 14.31 ± 0.3), with the diagnosis of refractory epilepsy using a clinical/psychopathological method and psychometric scales. Marked non-psychotic mental disorders of varying severity were observed in all patients. ⋯ The significant (p<0.01) improvement in cognitive functions and speech were found in 81.6% cases. The treatment reduced stress and improved mood in 63.1% of patients.
-
Zh Nevrol Psikhiatr · Jan 2009
Randomized Controlled Trial Comparative Study[Vitamin B complex (milgamma) in the treatment of vertebrogenic lumbosacral radiculopathy].
An open controlled study of efficacy of the vitamin B complex (milgamma) has been performed in 38 patients with vertebrogenic lumbosacral radiculopathy suffered from moderate or severe pain during 1 month or longer. Patients have been randomized into 2 equal groups: in the main group milgamma has been prescribed in the combination with diclofenac; patients of the control group have received diclofenac only. Treatment efficacy has been assessed by clinical scales in the 10th and 24th days, and by the results of telephone interview after 3 and 6 months. ⋯ At the 3rd months, between-group differences were still significant (the pain was absent or minimal in 63% patients of the main group and 34% of the control one). The results revealed the potentiation of analgesic effect of diclofenac by the vitamin B complex. Using of milgamma in combination with NSAIDS leads to the rapid and long-standing regress of pain syndrome in patients with lumbosacral radiculopathy.
-
Zh Nevrol Psikhiatr · Jan 2009
Randomized Controlled Trial Multicenter Study Comparative Study[Baclosan (baclofen) in the treatment of back pains: results of a multicenter study BRAVO].
-
Zh Nevrol Psikhiatr · Jan 2006
Randomized Controlled Trial Multicenter Study[A randomized, double blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke].
To study the efficacy and safety of tolperisone--a centrally acting muscle relaxant with membrane stabilizing activity--in the treatment of stroke-related spasticity. This was a randomized, double-blind, placebo-controlled, multicenter study with parallel groups. Treatment lasted 12 weeks and was started with a titration period of variable length (dose range 300-900 mg tolperisone daily). ⋯ No withdrawals caused by adverse events were reported in the tolperisone group. The findings of the present study demonstrate the efficacy and excellent tolerance of tolperisone in the treatment of spastic hypertonia following cerebral stroke. Study data further suggest that an individual dose titration which may exceed the recommended maximum dose of 450 mg daily results in optimized therapeutic benefit.